Celltrion通过FDA审核候选产品扩展美国业务，提升药品产能，推动肿瘤学供应链的发展。 Celltrion expands U.S. operations, boosts drug capacity, and advances oncology pipeline with FDA-reviewed candidates.

Celltrion宣布了扩大美国制造和研发活动的计划,包括获得新泽西的Eli Lilly设施,增加66 000升毒品药用能力,到2030年将扩大到132 000升。 Celltrion announced plans to expand its U.S. manufacturing and R&D presence, including acquiring an Eli Lilly facility in New Jersey to add 66,000L of drug substance capacity, with future expansion to 132,000L by 2030. 该公司披露了在创新性药物管道方面取得的进展,在林业发展局的审查中,有3名抗体药物联合候选人,其中1人获得了肺癌的快速指认。 The company revealed progress on its innovative drug pipeline, with three antibody-drug conjugate candidates in FDA review, one receiving Fast Track designation for lung cancer. 细胞预计到2028年将有多达16种新的药物应用,包括10个ADC和4个多功能抗体,目标是到2030年将18种生物相似物商业化,到2038年将41种生物相似物商业化,转向以肿瘤为重点的创新。 Celltrion expects up to 16 new drug applications by 2028, including 10 ADCs and 4 multi-specific antibodies, and aims to commercialize 18 biosimilars by 2030 and 41 by 2038, shifting toward oncology-focused innovation.